vs
MYR GROUP INC.（MYRG）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
MYR GROUP INC.的季度营收约是Revvity的1.3倍（$973.5M vs $772.1M），Revvity净利率更高（12.7% vs 3.8%，领先9.0%），MYR GROUP INC.同比增速更快（17.3% vs 5.9%），Revvity自由现金流更多（$161.8M vs $84.9M），过去两年MYR GROUP INC.的营收复合增速更高（9.3% vs 9.0%）
MYR集团是美国知名电气建设服务提供商，业务覆盖输配电线路、变电站、工商业建筑及可再生能源领域的电气施工，旗下拥有12家电气建设子公司，在北美电力基建赛道拥有深厚的技术积累与项目交付能力。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
MYRG vs RVTY — 直观对比
营收规模更大
MYRG
是对方的1.3倍
$772.1M
营收增速更快
MYRG
高出11.5%
5.9%
净利率更高
RVTY
高出9.0%
3.8%
自由现金流更多
RVTY
多$76.9M
$84.9M
两年增速更快
MYRG
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $973.5M | $772.1M |
| 净利润 | $36.5M | $98.4M |
| 毛利率 | 11.4% | — |
| 营业利润率 | 4.8% | 14.5% |
| 净利率 | 3.8% | 12.7% |
| 营收同比 | 17.3% | 5.9% |
| 净利润同比 | 129.1% | 3.9% |
| 每股收益（稀释后） | $2.33 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MYRGRVTY
| Q4 25 | $973.5M | $772.1M | ||
| Q3 25 | $950.4M | $698.9M | ||
| Q2 25 | $900.3M | $720.3M | ||
| Q1 25 | $833.6M | $664.8M | ||
| Q4 24 | $829.8M | $729.4M | ||
| Q3 24 | $888.0M | $684.0M | ||
| Q2 24 | $828.9M | $691.7M | ||
| Q1 24 | $815.6M | $649.9M |
净利润MYRGRVTY
| Q4 25 | $36.5M | $98.4M | ||
| Q3 25 | $32.1M | $46.7M | ||
| Q2 25 | $26.5M | $53.9M | ||
| Q1 25 | $23.3M | $42.2M | ||
| Q4 24 | $16.0M | $94.6M | ||
| Q3 24 | $10.6M | $94.4M | ||
| Q2 24 | $-15.3M | $55.4M | ||
| Q1 24 | $18.9M | $26.0M |
毛利率MYRGRVTY
| Q4 25 | 11.4% | — | ||
| Q3 25 | 11.8% | 53.6% | ||
| Q2 25 | 11.5% | 54.5% | ||
| Q1 25 | 11.6% | 56.5% | ||
| Q4 24 | 10.4% | — | ||
| Q3 24 | 8.7% | 56.3% | ||
| Q2 24 | 4.9% | 55.7% | ||
| Q1 24 | 10.6% | 54.6% |
营业利润率MYRGRVTY
| Q4 25 | 4.8% | 14.5% | ||
| Q3 25 | 4.9% | 11.7% | ||
| Q2 25 | 4.4% | 12.6% | ||
| Q1 25 | 4.1% | 10.9% | ||
| Q4 24 | 3.6% | 16.3% | ||
| Q3 24 | 2.3% | 14.3% | ||
| Q2 24 | -2.5% | 12.4% | ||
| Q1 24 | 3.0% | 6.8% |
净利率MYRGRVTY
| Q4 25 | 3.8% | 12.7% | ||
| Q3 25 | 3.4% | 6.7% | ||
| Q2 25 | 2.9% | 7.5% | ||
| Q1 25 | 2.8% | 6.4% | ||
| Q4 24 | 1.9% | 13.0% | ||
| Q3 24 | 1.2% | 13.8% | ||
| Q2 24 | -1.8% | 8.0% | ||
| Q1 24 | 2.3% | 4.0% |
每股收益（稀释后）MYRGRVTY
| Q4 25 | $2.33 | $0.86 | ||
| Q3 25 | $2.05 | $0.40 | ||
| Q2 25 | $1.70 | $0.46 | ||
| Q1 25 | $1.45 | $0.35 | ||
| Q4 24 | $0.97 | $0.77 | ||
| Q3 24 | $0.65 | $0.77 | ||
| Q2 24 | $-0.91 | $0.45 | ||
| Q1 24 | $1.12 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $150.2M | $919.9M |
| 总债务越低越好 | $59.0M | — |
| 股东权益账面价值 | $660.4M | $7.3B |
| 总资产 | $1.6B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.09× | — |
8季度趋势，按日历期对齐
现金及短期投资MYRGRVTY
| Q4 25 | $150.2M | $919.9M | ||
| Q3 25 | $76.2M | $931.4M | ||
| Q2 25 | $23.0M | $991.8M | ||
| Q1 25 | $10.9M | $1.1B | ||
| Q4 24 | $3.5M | $1.2B | ||
| Q3 24 | $7.6M | $1.2B | ||
| Q2 24 | $1.9M | $2.0B | ||
| Q1 24 | $3.9M | $1.7B |
总债务MYRGRVTY
| Q4 25 | $59.0M | — | ||
| Q3 25 | $72.0M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $87.2M | — | ||
| Q4 24 | $74.4M | — | ||
| Q3 24 | $93.2M | — | ||
| Q2 24 | $45.1M | — | ||
| Q1 24 | $37.9M | — |
股东权益MYRGRVTY
| Q4 25 | $660.4M | $7.3B | ||
| Q3 25 | $617.6M | $7.4B | ||
| Q2 25 | $583.2M | $7.6B | ||
| Q1 25 | $548.7M | $7.6B | ||
| Q4 24 | $600.4M | $7.7B | ||
| Q3 24 | $588.5M | $7.9B | ||
| Q2 24 | $633.3M | $7.9B | ||
| Q1 24 | $663.7M | $7.8B |
总资产MYRGRVTY
| Q4 25 | $1.6B | $12.2B | ||
| Q3 25 | $1.6B | $12.1B | ||
| Q2 25 | $1.6B | $12.4B | ||
| Q1 25 | $1.5B | $12.4B | ||
| Q4 24 | $1.6B | $12.4B | ||
| Q3 24 | $1.6B | $12.8B | ||
| Q2 24 | $1.6B | $13.4B | ||
| Q1 24 | $1.6B | $13.4B |
负债/权益比MYRGRVTY
| Q4 25 | 0.09× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.15× | — | ||
| Q1 25 | 0.16× | — | ||
| Q4 24 | 0.12× | — | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | 0.07× | — | ||
| Q1 24 | 0.06× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $114.8M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $84.9M | $161.8M |
| 自由现金流率自由现金流/营收 | 8.7% | 21.0% |
| 资本支出强度资本支出/营收 | 3.1% | 2.6% |
| 现金转化率经营现金流/净利润 | 3.14× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $232.2M | $509.4M |
8季度趋势，按日历期对齐
经营现金流MYRGRVTY
| Q4 25 | $114.8M | $182.0M | ||
| Q3 25 | $95.6M | $138.5M | ||
| Q2 25 | $32.9M | $134.3M | ||
| Q1 25 | $83.3M | $128.2M | ||
| Q4 24 | $21.1M | $174.2M | ||
| Q3 24 | $35.6M | $147.9M | ||
| Q2 24 | $22.7M | $158.6M | ||
| Q1 24 | $7.7M | $147.6M |
自由现金流MYRGRVTY
| Q4 25 | $84.9M | $161.8M | ||
| Q3 25 | $65.4M | $120.0M | ||
| Q2 25 | $11.6M | $115.5M | ||
| Q1 25 | $70.2M | $112.2M | ||
| Q4 24 | $8.8M | $149.8M | ||
| Q3 24 | $18.0M | $125.6M | ||
| Q2 24 | $2.5M | $136.6M | ||
| Q1 24 | $-18.1M | $129.7M |
自由现金流率MYRGRVTY
| Q4 25 | 8.7% | 21.0% | ||
| Q3 25 | 6.9% | 17.2% | ||
| Q2 25 | 1.3% | 16.0% | ||
| Q1 25 | 8.4% | 16.9% | ||
| Q4 24 | 1.1% | 20.5% | ||
| Q3 24 | 2.0% | 18.4% | ||
| Q2 24 | 0.3% | 19.7% | ||
| Q1 24 | -2.2% | 20.0% |
资本支出强度MYRGRVTY
| Q4 25 | 3.1% | 2.6% | ||
| Q3 25 | 3.2% | 2.6% | ||
| Q2 25 | 2.4% | 2.6% | ||
| Q1 25 | 1.6% | 2.4% | ||
| Q4 24 | 1.5% | 3.4% | ||
| Q3 24 | 2.0% | 3.3% | ||
| Q2 24 | 2.4% | 3.2% | ||
| Q1 24 | 3.2% | 2.7% |
现金转化率MYRGRVTY
| Q4 25 | 3.14× | 1.85× | ||
| Q3 25 | 2.98× | 2.97× | ||
| Q2 25 | 1.24× | 2.49× | ||
| Q1 25 | 3.57× | 3.03× | ||
| Q4 24 | 1.32× | 1.84× | ||
| Q3 24 | 3.35× | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | 0.41× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MYRG
| Market Type Electrical Construction | $442.6M | 45% |
| Market Type Transmission | $330.3M | 34% |
| Market Type Distribution | $200.6M | 21% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
